SCHEMBL860732

SCHEMBL860732

COc1c(-c2cc3ccccc3c(=O)o2)cc(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 4/20 0.48
ALOX5 P09917 3/20 0.48
CYP3A4 P08684 3/20 0.45
CASP3 P42574 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CYP1A1 P04798 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MITF O75030 1/20 0.37
PDGFRB P09619 1/20 0.34
EGFR P00533 1/20 0.33
ERBB2 P04626 1/20 0.33
NPC1 O15118 1/20 0.33
AHR P35869 1/20 0.33
C1R P00736 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3406008 0.84 CYP3A4 (0.59) PTGESALOX5CYP3A4CYP1A1
SCHEMBL13030226 0.84 CYP3A4 (0.47) PTGESALOX5CYP3A4CASP3SENP7
SCHEMBL848159 0.82 CYP3A4 (0.47) CYP3A4CASP3SENP7KDM4EALDH1A1
SCHEMBL1543040 0.75 CYP3A4 (0.55) CYP3A4KDM4EALDH1A1HPGDTDP1
SCHEMBL1542685 0.75 CYP3A4 (0.55) CYP3A4CYP1A1PDGFRBEGFRERBB2
SCHEMBL2128598 0.74 CYP3A4 (0.54) CYP3A4ALDH1A1MAPTCYP1A1L3MBTL1
SCHEMBL2128925 0.74 CYP3A4 (0.54) CYP3A4KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL847054 0.73 CYP3A4 (0.59) CYP3A4KDM4EALDH1A1MAPTHPGD
SCHEMBL1542385 0.73 CYP3A4 (0.64) CYP3A4KDM4EALDH1A1MAPTCYP1A1
SCHEMBL13065110 0.72 CYP3A4 (0.44) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432554-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-03-28 EP claimed
WO-2010133528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-25 WO claimed
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS CHIN ELBERT 2010-11-25 US claimed
EP-2432554-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2012-03-28 EP disclosed
WO-2010133528-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-11-25 WO disclosed
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS CHIN ELBERT 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297073-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B PTGES 2897/4885ALOX5 3597/4885CYP3A4 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.